display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
castration-resistant prostate cancer (CRPC)
metastatic (mCRPC) - 1st line (L1)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone CA184-043 CA184-095
anti-PD-(L)1
pembrolizumab based treatment KEYNOTE-921

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons